Biomark Diagnostics Inc.

CNSX:BUX Stock Report

Market Cap: CA$13.0m

Biomark Diagnostics Valuation

Is BUX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BUX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BUX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BUX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BUX?

Key metric: As BUX barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for BUX. This is calculated by dividing BUX's market cap by their current book value.
What is BUX's PB Ratio?
PB Ratio-20.1x
Book-CA$649.61k
Market CapCA$13.03m

Price to Book Ratio vs Peers

How does BUX's PB Ratio compare to its peers?

The above table shows the PB ratio for BUX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average16.3x
WLLW Willow Biosciences
59.2xn/aCA$11.5m
CYTO Cytophage Technologies
3.3xn/aCA$17.3m
CSCI COSCIENS Biopharma
0.5xn/aCA$12.9m
IBT IBEX Technologies
2.5xn/aCA$35.3m
BUX Biomark Diagnostics
n/an/aCA$9.0m

Price-To-Book vs Peers: BUX has negative equity and a Price-To-Book Ratio (-20.1x) compared to the peer average (16.3x).

Price to Book Ratio vs Industry

How does BUX's PB Ratio compare vs other companies in the CA Biotechs Industry?

2 CompaniesPrice / BookEstimated GrowthMarket Cap
QPT Quest PharmaTech
0.3xn/aUS$4.24m
CURE.X Biocure Technology
0.2xn/aUS$224.17k
No more companies available in this PB range
BUX is unprofitableIndustry Avg. 2.8xNo. of Companies2PB01.22.43.64.86+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: BUX has negative equity and a Price-To-Book Ratio (-20.1x) compared to the Canadian Biotechs industry average (2.6x).

Price to Book Ratio vs Fair Ratio

What is BUX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BUX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-20.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BUX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Verano Holdings

CA$722.2m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.02

7D

-14.8%

1Y

-65.2%

Fennec Pharmaceuticals

US$145.9m

Operates as a biopharmaceutical company in the United States.

FRX

US$7.35

7D

30.1%

1Y

-38.9%

Medexus Pharmaceuticals

CA$60.4m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.45

7D

15.6%

1Y

61.2%